1
|
Koga M, Inada K, Yamada A, Maruoka K, Yamauchi A. Nalmefene, an opioid receptor modulator, aggravates atherosclerotic plaque formation in apolipoprotein E knockout mice by enhancing oxidized low-density lipoprotein uptake in macrophages. Biochem Biophys Rep 2024; 38:101688. [PMID: 38560051 PMCID: PMC10979050 DOI: 10.1016/j.bbrep.2024.101688] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/22/2024] [Revised: 03/14/2024] [Accepted: 03/18/2024] [Indexed: 04/04/2024] Open
Abstract
Nalmefene, an antagonist of mu- and delta-opioid receptors and a partial agonist of kappa-opioid receptors, has shown promise in reducing alcohol consumption among patients with alcohol dependence. Opioid receptors play pivotal roles in various physiological processes, including those related to peripheral inflammatory diseases such as colitis and arthritis, as well as functions in the immune system and phagocytosis. Atherosclerosis, a chronic inflammatory disease, progresses through the phagocytosis and uptake of oxidized low-density lipoprotein (oxLDL) by macrophages in atherosclerotic plaques. Despite this knowledge, it remains unclear whether nalmefene influences the formation of atherosclerotic plaques and increases the risk of serious cardiovascular events. This study aims to elucidate the impact of nalmefene on atherosclerosis in apolipoprotein E knockout (ApoE KO) mice and peritoneal macrophages in vitro. In this experiment, 8-week-old male ApoE KO mice were fed a high-fat diet intraperitoneally administered either vehicle (saline) or nalmefene (1 mg and 3 mg kg-1 day-1) for 21 days. Oil red O-staining and immunohistochemistry with an anti-MOMA2 (monocyte/macrophage) antibody showed that a dose-dependent increase in atherosclerotic plaque formation and augmentation of macrophage-rich plaque formation in ApoE-KO mice. Further investigations focused on the effects of nalmefene on the expression of scavenger receptor CD36 in RAW264.7 cells, conducted through western blotting analysis. Nalmefene demonstrated a significant increase in CD36 protein expression in RAW264.7 cells. To explore the impact on oxidized LDL uptake in peritoneal macrophages, cells were treated with nalmefene (300 μg/mL) for 24 h, followed by the addition of DiI-labeled oxLDL (DiI-oxLDL) for 4 h. Nalmefene significantly enhanced DiI-oxLDL uptake in macrophages. Additionally, treatment with nalmefene (300 μg/mL) for 24 h decreased the mRNA expression of mu-, delta-, and kappa-opioid receptors in RAW264.7 cells. In conclusion, nalmefene may augment oxLDL uptake by macrophages through increased CD36 expression and decreased opioid receptor, thereby contributing to atherosclerotic plaque formation and vulnerability. Consequently, the use of nalmefene may be associated with an elevated risk of cardiovascular events.
Collapse
Affiliation(s)
- Mitsuhisa Koga
- Department of Drug Delivery, Faculty of Pharmaceutical Sciences, Fukuoka University, 8-19-1 Nanakuma, Jonan-ku, Fukuoka, 814-0180, Japan
| | - Koshun Inada
- Department of Pharmaceutical Care and Health Sciences, Faculty of Pharmaceutical Sciences, Fukuoka University, 8-19-1 Nanakuma, Jonan-ku, Fukuoka, 814-0180, Japan
| | - Ayano Yamada
- Department of Drug Delivery, Faculty of Pharmaceutical Sciences, Fukuoka University, 8-19-1 Nanakuma, Jonan-ku, Fukuoka, 814-0180, Japan
| | - Kana Maruoka
- Department of Pharmaceutical Care and Health Sciences, Faculty of Pharmaceutical Sciences, Fukuoka University, 8-19-1 Nanakuma, Jonan-ku, Fukuoka, 814-0180, Japan
| | - Atsushi Yamauchi
- Department of Pharmaceutical Care and Health Sciences, Faculty of Pharmaceutical Sciences, Fukuoka University, 8-19-1 Nanakuma, Jonan-ku, Fukuoka, 814-0180, Japan
| |
Collapse
|
2
|
Ma W, Jia K, Cheng H, Xu H, Li Z, Zhang H, Xie H, Sun H, Yi L, Chen Z, Duan S, Sano M, Fukuda K, Lu L, Gao F, Zhang R, Yan X. Orphan Nuclear Receptor NR4A3 Promotes Vascular Calcification via Histone Lactylation. Circ Res 2024; 134:1427-1447. [PMID: 38629274 DOI: 10.1161/circresaha.123.323699] [Citation(s) in RCA: 1] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 09/14/2023] [Accepted: 04/02/2024] [Indexed: 05/25/2024]
Abstract
BACKGROUND Medial arterial calcification is a chronic systemic vascular disorder distinct from atherosclerosis and is commonly observed in patients with chronic kidney disease, diabetes, and aging individuals. We previously showed that NR4A3 (nuclear receptor subfamily 4 group A member 3), an orphan nuclear receptor, is a key regulator in apo (apolipoprotein) A-IV-induced atherosclerosis progression; however, its role in vascular calcification is poorly understood. METHODS We generated NR4A3-/- mice and 2 different types of medial arterial calcification models to investigate the biological roles of NR4A3 in vascular calcification. RNA-seq was performed to determine the transcriptional profile of NR4A3-/- vascular smooth muscle cells under β-glycerophosphate treatment. We integrated Cleavage Under Targets and Tagmentation analysis and RNA-seq data to further investigate the gene regulatory mechanisms of NR4A3 in arterial calcification and target genes regulated by histone lactylation. RESULTS NR4A3 expression was upregulated in calcified aortic tissues from chronic kidney disease mice, 1,25(OH)2VitD3 overload-induced mice, and human calcified aorta. NR4A3 deficiency preserved the vascular smooth muscle cell contractile phenotype, inhibited osteoblast differentiation-related gene expression, and reduced calcium deposition in the vasculature. Further, NR4A3 deficiency lowered the glycolytic rate and lactate production during the calcification process and decreased histone lactylation. Mechanistic studies further showed that NR4A3 enhanced glycolysis activity by directly binding to the promoter regions of the 2 glycolysis genes ALDOA and PFKL and driving their transcriptional initiation. Furthermore, histone lactylation promoted medial calcification both in vivo and in vitro. NR4A3 deficiency inhibited the transcription activation and expression of Phospho1 (phosphatase orphan 1). Consistently, pharmacological inhibition of Phospho1 attenuated calcium deposition in NR4A3-overexpressed vascular smooth muscle cells, whereas overexpression of Phospho1 reversed the anticalcific effect of NR4A3 deficiency in vascular smooth muscle cells. CONCLUSIONS Taken together, our findings reveal that NR4A3-mediated histone lactylation is a novel metabolome-epigenome signaling cascade mechanism that participates in the pathogenesis of medial arterial calcification.
Collapse
MESH Headings
- Animals
- Vascular Calcification/metabolism
- Vascular Calcification/genetics
- Vascular Calcification/pathology
- Mice
- Mice, Knockout
- Humans
- Histones/metabolism
- Muscle, Smooth, Vascular/metabolism
- Muscle, Smooth, Vascular/pathology
- Mice, Inbred C57BL
- Nuclear Receptor Subfamily 4, Group A, Member 3/metabolism
- Nuclear Receptor Subfamily 4, Group A, Member 3/genetics
- Male
- Myocytes, Smooth Muscle/metabolism
- Myocytes, Smooth Muscle/pathology
- Cells, Cultured
- DNA-Binding Proteins
- Nerve Tissue Proteins
- Receptors, Steroid
- Receptors, Thyroid Hormone
Collapse
Affiliation(s)
- Wenqi Ma
- Department of Cardiovascular Medicine, Ruijin Hospital (W.M., K.J., H.C., Z.L., H.Z., H.X., L.Z., Z.W., Y.C., H.S., L.Y., Z.C., L.L., R.Z., X.Y.), Shanghai Jiao Tong University School of Medicine, China
- Institute of Cardiovascular Diseases (W.M., K.J., H.C., Z.L., H.Z., H.X., L.Z., Z.W., Y.C., H.S., L.Y., Z.C., L.L., R.Z., X.Y.), Shanghai Jiao Tong University School of Medicine, China
| | - Kangni Jia
- Department of Cardiovascular Medicine, Ruijin Hospital (W.M., K.J., H.C., Z.L., H.Z., H.X., L.Z., Z.W., Y.C., H.S., L.Y., Z.C., L.L., R.Z., X.Y.), Shanghai Jiao Tong University School of Medicine, China
- Institute of Cardiovascular Diseases (W.M., K.J., H.C., Z.L., H.Z., H.X., L.Z., Z.W., Y.C., H.S., L.Y., Z.C., L.L., R.Z., X.Y.), Shanghai Jiao Tong University School of Medicine, China
| | - Haomai Cheng
- Department of Cardiovascular Medicine, Ruijin Hospital (W.M., K.J., H.C., Z.L., H.Z., H.X., L.Z., Z.W., Y.C., H.S., L.Y., Z.C., L.L., R.Z., X.Y.), Shanghai Jiao Tong University School of Medicine, China
- Institute of Cardiovascular Diseases (W.M., K.J., H.C., Z.L., H.Z., H.X., L.Z., Z.W., Y.C., H.S., L.Y., Z.C., L.L., R.Z., X.Y.), Shanghai Jiao Tong University School of Medicine, China
| | - Hong Xu
- Department of Cardiovascular Medicine, Ruijin Hospital (W.M., K.J., H.C., Z.L., H.Z., H.X., L.Z., Z.W., Y.C., H.S., L.Y., Z.C., L.L., R.Z., X.Y.), Shanghai Jiao Tong University School of Medicine, China
| | - Zhigang Li
- Department of Cardiovascular Medicine, Ruijin Hospital (W.M., K.J., H.C., Z.L., H.Z., H.X., L.Z., Z.W., Y.C., H.S., L.Y., Z.C., L.L., R.Z., X.Y.), Shanghai Jiao Tong University School of Medicine, China
- Institute of Cardiovascular Diseases (W.M., K.J., H.C., Z.L., H.Z., H.X., L.Z., Z.W., Y.C., H.S., L.Y., Z.C., L.L., R.Z., X.Y.), Shanghai Jiao Tong University School of Medicine, China
| | - Hang Zhang
- Department of Cardiovascular Medicine, Ruijin Hospital (W.M., K.J., H.C., Z.L., H.Z., H.X., L.Z., Z.W., Y.C., H.S., L.Y., Z.C., L.L., R.Z., X.Y.), Shanghai Jiao Tong University School of Medicine, China
- Institute of Cardiovascular Diseases (W.M., K.J., H.C., Z.L., H.Z., H.X., L.Z., Z.W., Y.C., H.S., L.Y., Z.C., L.L., R.Z., X.Y.), Shanghai Jiao Tong University School of Medicine, China
| | - Hongyang Xie
- Institute of Cardiovascular Diseases (W.M., K.J., H.C., Z.L., H.Z., H.X., L.Z., Z.W., Y.C., H.S., L.Y., Z.C., L.L., R.Z., X.Y.), Shanghai Jiao Tong University School of Medicine, China
| | - Hang Sun
- Department of Cardiovascular Medicine, Ruijin Hospital (W.M., K.J., H.C., Z.L., H.Z., H.X., L.Z., Z.W., Y.C., H.S., L.Y., Z.C., L.L., R.Z., X.Y.), Shanghai Jiao Tong University School of Medicine, China
| | - Lei Yi
- Department of Cardiovascular Medicine, Ruijin Hospital (W.M., K.J., H.C., Z.L., H.Z., H.X., L.Z., Z.W., Y.C., H.S., L.Y., Z.C., L.L., R.Z., X.Y.), Shanghai Jiao Tong University School of Medicine, China
| | - Zhiyong Chen
- Department of Cardiovascular Medicine, Ruijin Hospital (W.M., K.J., H.C., Z.L., H.Z., H.X., L.Z., Z.W., Y.C., H.S., L.Y., Z.C., L.L., R.Z., X.Y.), Shanghai Jiao Tong University School of Medicine, China
| | - Shengzhong Duan
- Department of Cardiovascular Medicine, Ruijin Hospital (W.M., K.J., H.C., Z.L., H.Z., H.X., L.Z., Z.W., Y.C., H.S., L.Y., Z.C., L.L., R.Z., X.Y.), Shanghai Jiao Tong University School of Medicine, China
- Laboratory of Oral Microbiota and Systemic Diseases, Shanghai Ninth People's Hospital, College of Stomatology (S.D.), Shanghai Jiao Tong University School of Medicine, China
- Department of Cardiovascular Medicine, State Key Laboratory of Medical Genomics, Shanghai Key Laboratory of Hypertension, Shanghai Institute of Hypertension, Ruijin Hospital (S.D.), Shanghai Jiao Tong University School of Medicine, China
| | - Motoaki Sano
- Department of Cardiology, Keio University School of Medicine, Tokyo, Japan (M.S., K.F.)
| | - Keiichi Fukuda
- Department of Cardiology, Keio University School of Medicine, Tokyo, Japan (M.S., K.F.)
| | - Lin Lu
- Department of Cardiovascular Medicine, Ruijin Hospital (W.M., K.J., H.C., Z.L., H.Z., H.X., L.Z., Z.W., Y.C., H.S., L.Y., Z.C., L.L., R.Z., X.Y.), Shanghai Jiao Tong University School of Medicine, China
| | - Fei Gao
- Beijing Anzhen Hospital, Capital Medical University, China (F.G.)
| | - Ruiyan Zhang
- Department of Cardiovascular Medicine, Ruijin Hospital (W.M., K.J., H.C., Z.L., H.Z., H.X., L.Z., Z.W., Y.C., H.S., L.Y., Z.C., L.L., R.Z., X.Y.), Shanghai Jiao Tong University School of Medicine, China
| | - Xiaoxiang Yan
- Department of Cardiovascular Medicine, Ruijin Hospital (W.M., K.J., H.C., Z.L., H.Z., H.X., L.Z., Z.W., Y.C., H.S., L.Y., Z.C., L.L., R.Z., X.Y.), Shanghai Jiao Tong University School of Medicine, China
| |
Collapse
|
7
|
Atawia RT, Batori R, Jordan CR, Kennard S, Antonova G, Bruder-Nascimento T, Mehta V, Saeed MI, Patel VS, Fukai T, Ushio-Fukai M, Huo Y, Fulton DJR, de Chantemèle EJB. Type 1 Diabetes Impairs Endothelium-Dependent Relaxation Via Increasing Endothelial Cell Glycolysis Through Advanced Glycation End Products, PFKFB3, and Nox1-Mediated Mechanisms. Hypertension 2023; 80:2059-2071. [PMID: 37729634 PMCID: PMC10514399 DOI: 10.1161/hypertensionaha.123.21341] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/16/2023] [Accepted: 08/02/2023] [Indexed: 09/22/2023]
Abstract
BACKGROUND Type 1 diabetes (T1D) is a major cause of endothelial dysfunction. Although cellular bioenergetics has been identified as a new regulator of vascular function, whether glycolysis, the primary bioenergetic pathway in endothelial cells (EC), regulates vascular tone and contributes to impaired endothelium-dependent relaxation (EDR) in T1D remains unknown. METHODS Experiments were conducted in Akita mice with intact or selective deficiency in EC PFKFB3 (6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase 3), the main regulator of glycolysis. Seahorse analyzer and myography were employed to measure glycolysis and mitochondrial respiration, and EDR, respectively, in aortic explants. EC PFKFB3 (Ad-PFKFB3) and glycolysis (Ad-GlycoHi) were increased in situ via adenoviral transduction. RESULTS T1D increased EC glycolysis and elevated EC expression of PFKFB3 and NADPH oxidase Nox1 (NADPH oxidase homolog 1). Functionally, pharmacological and genetic inhibition of PFKFB3 restored EDR in T1D, while in situ aorta EC transduction with Ad-PFKFB3 or Ad-GlycoHi reproduced the impaired EDR associated with T1D. Nox1 inhibition restored EDR in aortic rings from Akita mice, as well as in Ad-PFKFB3-transduced aorta EC and lactate-treated wild-type aortas. T1D increased the expression of the advanced glycation end product precursor methylglyoxal in the aortas. Exposure of the aortas to methylglyoxal impaired EDR, which was prevented by PFKFB3 inhibition. T1D and exposure to methylglyoxal increased EC expression of HIF1α (hypoxia-inducible factor 1α), whose inhibition blunted methylglyoxal-mediated EC PFKFB3 upregulation. CONCLUSIONS EC bioenergetics, namely glycolysis, is a new regulator of vasomotion and excess glycolysis, a novel mechanism of endothelial dysfunction in T1D. We introduce excess methylglyoxal, HIF1α, and PFKFB3 as major effectors in T1D-mediated increased EC glycolysis.
Collapse
Affiliation(s)
- Reem T. Atawia
- Vascular Biology Center, Medical College of Georgia, Augusta University, Augusta, Georgia, USA
- Department of Pharmacology and Toxicology, Faculty of Pharmacy, Ain Shams University, Abasia, Cairo, Egypt
| | - Robert Batori
- Vascular Biology Center, Medical College of Georgia, Augusta University, Augusta, Georgia, USA
| | - Coleton R. Jordan
- Vascular Biology Center, Medical College of Georgia, Augusta University, Augusta, Georgia, USA
| | - Simone Kennard
- Vascular Biology Center, Medical College of Georgia, Augusta University, Augusta, Georgia, USA
| | - Galina Antonova
- Vascular Biology Center, Medical College of Georgia, Augusta University, Augusta, Georgia, USA
| | | | - Vinay Mehta
- Vascular Biology Center, Medical College of Georgia, Augusta University, Augusta, Georgia, USA
| | - Muhammad I. Saeed
- Department of Surgery, Medical College of Georgia, Augusta University, Augusta, Georgia, USA
| | - Vijay S Patel
- Department of Surgery, Medical College of Georgia, Augusta University, Augusta, Georgia, USA
| | - Tohru Fukai
- Vascular Biology Center, Medical College of Georgia, Augusta University, Augusta, Georgia, USA
| | - Masuko Ushio-Fukai
- Vascular Biology Center, Medical College of Georgia, Augusta University, Augusta, Georgia, USA
| | - Yuqing Huo
- Vascular Biology Center, Medical College of Georgia, Augusta University, Augusta, Georgia, USA
| | - David JR Fulton
- Vascular Biology Center, Medical College of Georgia, Augusta University, Augusta, Georgia, USA
| | | |
Collapse
|